| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 2,600 | $45.09 | $117,239.00 | -1.5% | |
| Mar 20, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 20,000 | $19.43 | $388,638.00 | -4.2% | |
| Mar 19, 2018 | CPIX Cumberland Pharmaceuticals Inc | Bonner Michael | Chief Financial Officer | Buy | 300 | $6.72 | $2,016.00 | +1.9% | |
| Mar 19, 2018 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceuticals International AG | 10% Owner | Sell | 7,420,625 | $18.67 | $138,543,068.75 | -100% | |
| Mar 19, 2018 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceuticals International AG | 10% Owner | Buy | 7,420,625 | $18.67 | $138,543,068.75 | New | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 2,358 | $18.38 | $43,340.04 | -44.2% | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 571 | $17.88 | $10,208.34 | -11.4% | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 1,297 | $17.89 | $23,205.92 | -100% | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 348 | $17.88 | $6,221.54 | -2.4% | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, Growth Markets Commercial | Sell | 457 | $17.89 | $8,176.64 | -7.4% | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | McClellan Michael James | EVP, Chief Financial Officer | Sell | 287 | $17.88 | $5,130.99 | -2.5% | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 943 | $17.88 | $16,858.95 | -100% | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 1,179 | $17.88 | $21,078.16 | -45.9% | |
| Mar 19, 2018 | ANIP Ani Pharmaceuticals Inc | Raynor Daniel | Director | Sell | 7,215 | $60.85 | $439,047.06 | -1.2% | |
| Mar 16, 2018 | LLY Eli Lilly & Co | Smiley Joshua L58 | SVP And CFO | Sell | 3,000 | $79.20 | $237,600.00 | -13.0% | |
| Mar 15, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 16,598 | $19.90 | $330,318.46 | -36.5% | |
| Mar 15, 2018 | DVAX Dynavax Technologies Corp | Novack David F73 | Senior Vice President | Sell | 16,109 | $16.30 | $262,604.09 | -100% | |
| Mar 15, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 24,000 | $40.05 | $961,200.00 | -40.0% | |
| Mar 15, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 24,000 | $40.05 | $961,200.00 | -40.0% | |
| Mar 14, 2018 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | See Remarks | Sell | 11,492 | $16.60 | $190,775.24 | -6.5% | |
| Mar 14, 2018 | ANIP Ani Pharmaceuticals Inc | Marshbanks Tracy | Director | Sell | 1,912 | $63.10 | $120,647.20 | -0.4% | |
| Mar 14, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 700 | $20.45 | $14,315.00 | -0.2% | |
| Mar 14, 2018 | ANIP Ani Pharmaceuticals Inc | Raynor Daniel | Director | Sell | 27,964 | $62.24 | $1,740,552.05 | -2.3% | |
| Mar 14, 2018 | ANIP Ani Pharmaceuticals Inc | Przybyl Arthur | President And CEO | Sell | 40,000 | $61.83 | $2,473,142.75 | -6.4% | |
| Mar 13, 2018 | DVAX Dynavax Technologies Corp | Novack David F73 | Senior Vice President | Sell | 34,214 | $16.52 | $565,105.15 | -36.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.